Amyloid-targeting imaging agents such as radiolabeled amyloid targeting molecules and amyloid targeting molecule-chelator conjugates for imaging, e.g., amyloid plaques in vivo, and/or for the treatment of amyloidosis disorders. The invention provides amyloid-targeting imaging agents that are useful for imaging sites of amyloid disease. Imaging agents of the invention are capable of binding specifically to amyloid plaques, as an aid in diagnosis and/or early treatment of amyloidosis disorders.
RELATED APPLICATIONS
This application claims the benefit of priority under 35 U.S.C. 119(e) to copending U.S. Provisional Application No. 60/443,291, filed Jan. 28, 2003. This application is also a continuation-in-part of U.S. patent application Ser. No. 09/915,092, filed Jul. 24, 2001 which claims priority to U.S. Provisional Application No. 60/220,808, filed Jul. 25, 2000, the entire contents of each of which are incorporated herein by reference.
